SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer

• DOI: 10.1186/s12920-022-01266-0
• Publication Date: 2022-05-17T08:03:34Z
• Authors: Wei Hou; Guo-Sheng Li; Li Gao; Hui-Ping Lu; Hua-Fu Zhou; Jin-Liang Kong; Gang Chen; Shuang Xia; Hong-Yu Wei
• Keywords: Clinical Significance

The roles and clinical values of synaptojanin 2 (SYNJ2) in lung squamous cell carcinoma (LUSC) remain unclear.